$PIII Balance Sheet | Understand Stock

$PIII

$3.81 -$0.07 (1.8%) Close

$PIII Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2025 As of Jun 30, 2026	Q1 FY2025 As of Mar 31, 2026	Q4 FY2024 As of Dec 31, 2025	Q3 FY2024 As of Sep 30, 2025	Q2 FY2024 As of Jun 30, 2025	Q1 FY2024 As of Mar 31, 2025	Q4 FY2023 As of Dec 31, 2024	Q3 FY2023 As of Sep 30, 2024	Q2 FY2023 As of Jun 30, 2024	Q1 FY2023 As of Mar 31, 2024	Q4 FY2022 As of Dec 31, 2023	Q3 FY2022 As of Sep 30, 2023	Q2 FY2022 As of Jun 30, 2023	Q1 FY2022 As of Mar 31, 2023	Q4 FY2021 As of Dec 31, 2022	Q3 FY2021 As of Sep 30, 2022	Q2 FY2021 As of Jun 30, 2022	Q4 FY2020 As of Dec 31, 2021	Q1 FY2021 As of Mar 31, 2022	Q3 FY2020 As of Sep 30, 2021
ASSETS
CURRENT ASSETS:
Cash
Prepaid expenses
Restricted cash
Health plan receivable, net of allowance for credit losses of $281
Clinic fees, insurance and other receivable
Other receivables
Prepaid expenses and other current assets
Assets held for sale
TOTAL CURRENT ASSETS

Deferred Offering Costs
Cash and securities held in Trust Account
Property and Equipment
Less: Accumulated Depreciation
Property and equipment, net
Goodwill
Intangible assets, net
Notes Receivable, Net
Right of Use Asset
Other long-term assets
TOTAL LONG-TERM ASSETS
TOTAL ASSETS

LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ (DEFICIT) EQUITY
CURRENT LIABILITIES:
Accounts Payable and Accrued Expenses
Accounts payable
Accrued offering costs
Promissory note – related party
Accrued expenses and other current liabilities
Accrued payroll
Health plan settlements payable
Claims payable
Premium deficiency reserve
Accrued interest
Current portion of long-term debt
Liabilities held for sale
Short-term debt
TOTAL CURRENT LIABILITIES
Other long-term liabilities

Operating lease liability, net
Warrant liabilities
Contingent consideration
Long-term debt, net
TOTAL LONG-TERM LIABILITIES
TOTAL LIABILITIES
MEZZANINE EQUITY:
Redeemable non-controlling interest
Class D Units Subject to Possible Redemption (Predecessor), 16,130,034 Units Net of Issuance Costs $2,958,446, Plus Preferred Returns $4,567,346
Common stock, shares issued (in shares)
Class A Common Stock
Class V common
Class V Common Stock

Common stock, shares outstanding (in shares)
Class A Common Stock
Class V common
Class V Common Stock

STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred stock
Series A Preferred Stock
Series B Preferred Stock
Series C Preferred Stock
Series D Preferred Stock
Common stock
Class A Common Stock
Class V common
Class V Common Stock

Additional paid in capital
Accumulated deficit
STOCKHOLDERS’ (DEFICIT) EQUITY
Class V Common Stock
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY

Non-controlling interest
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)
TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY (DEFICIT)

Comments